What Is Lugdunin? Definition and What Research Reports

Lugdunin is a small, non-ribosomally synthesised cyclic peptide antibiotic produced by Staphylococcus lugdunensis, a coagulase-negative staphylococcus that lives on human skin and in the nose. It belongs to a compound class the literature calls fibupeptides, named for the fibula-like thiazolidine ring that closes the macrocycle and links the peptide backbone to a non-peptidic thiazolidine unit. Researchers described the molecule as being exported from its producer organism by dedicated ABC transporters that also protect the producer from its own antibiotic, a secretion-plus-self-resistance arrangement characterised in a 2020 study in Antimicrobial Agents and Chemotherapy. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, treatment or medication.

The term at a glance

What class of molecule is lugdunin?

Lugdunin sits at the boundary between classical peptides and peptide-like natural products. Its backbone is built from amino acid building blocks by non-ribosomal peptide synthetase enzymes rather than by ribosomes, and the ring is closed through a thiazolidine heterocycle rather than a simple amide bond. That heterocycle is central to how chemists discuss the molecule: a 2019 Angewandte Chemie paper on synthetic lugdunin analogues reported that specific structural motifs were essential for antimicrobial action and for the molecule's proton translocation capability, meaning that the ring and its stereochemistry were not incidental decoration.

Because of this hybrid character, lugdunin is usually grouped with membrane-active antimicrobial peptides in reviews and mechanism papers, but it is not a signalling peptide, a hormone analogue, or a receptor agonist. It has no relationship to the therapeutic peptide categories such as GLP-1 analogues or growth-factor fragments; it is an antibacterial natural product studied in microbiology and medicinal chemistry.

Where lugdunin comes from

Staphylococcus lugdunensis — the organism that gives the molecule its name — was profiled in a 2021 Clinical Microbiology Reviews review as a skin commensal with invasive pathogenic potential, meaning it is normally a harmless resident of human skin and nasal mucosa but has been associated with serious infections such as endocarditis in clinical settings. Not every isolate carries the biosynthetic machinery. Genomic surveys have looked specifically at how often the lug operon is present: a 2025 whole-genome sequencing study examined the lug operon, SCCmec elements, antimicrobial resistance determinants, mobile genetic elements and sequence types across clinical isolates. Phenotypic and genotypic variation across clinical collections has also been characterised in a French retrospective cohort study of clinical S. lugdunensis isolates and in a 2022 analysis of antimicrobial resistance and antimicrobial activity among isolates obtained from two Spanish hospitals.

How the term is used in peptide research

In the published literature, "lugdunin" appears in three fairly distinct senses, and reading which sense is intended usually clarifies an otherwise confusing abstract:

• The natural product. The molecule isolated from, or produced by, S. lugdunensis cultures — the sense used in secretion and self-resistance work such as the 2020 ABC transporter study.
• The genetic trait. Shorthand for carriage of the lug operon in a bacterial isolate, as used in genomic surveys like the 2025 whole-genome sequencing analysis.
• The chemical scaffold. A starting point for synthetic analogues and conjugates, as in a 2021 Journal of Medicinal Chemistry report describing a new efficient synthesis and broad exploitation of the MRSA-antimicrobial structure.

What the published literature reports

Mechanism in membranes

Mechanistic work has centred on how the molecule interacts with lipid bilayers. The 2024 Nature Communications study reported that the antimicrobial fibupeptide lugdunin formed water-filled channel structures in lipid membranes, a description consistent with earlier analogue work in which researchers reported proton translocation capability that tracked with defined structural motifs.

Antibacterial scope in laboratory models

Chemistry-led papers have framed lugdunin as an anti-MRSA scaffold. The 2021 synthesis paper described distinct lugdunins generated from a new efficient synthetic route and the broad exploitation of the molecule's MRSA-antimicrobial structure. The scaffold has also been carried into other disease areas: a 2024 Bioorganic Chemistry paper described the design, synthesis and anti-plasmodial activity of mortiamide–lugdunin conjugates.

Skin, nose and host immunity

Beyond direct killing, lugdunin has been studied as a modulator of host defence. A 2019 Nature Communications study reported that lugdunin amplified innate immune responses in the skin, acting in synergy with host- and microbiota-derived factors. Colonisation research has added nuance about how much of the commensal's competitive effect is attributable to the peptide alone: a 2024 Microbiome study reported that the Staphylococcus aureus-antagonising activity of nasal S. lugdunensis depended on siderophore piracy, and a 2025 Microbiology study reported that S. lugdunensis did not exert competitive exclusion on human corneocytes. Taken together, the studies describe a picture in which lugdunin is one factor among several rather than a single explanation for staphylococcal competition.

Adverse Events and Safety: What Studies Report

The verified literature summarised here consists of microbiology, genomics, chemistry and preclinical mechanism work; it does not contain human clinical trials of lugdunin, and therefore reports no human dosing, no pharmacokinetics and no catalogue of adverse events. The closest safety-adjacent material concerns the producer organism rather than the peptide: the 2021 review described S. lugdunensis as a commensal with invasive pathogenic potential, and the 2022 hospital-isolate analysis characterised antimicrobial resistance patterns alongside antimicrobial activity. Any statement about tolerability in people would go beyond what these papers examined.

Regulatory status

Lugdunin is not an approved drug in the United States or European Union, and no approved product contains it. Materials sold for laboratory work are handled as research-use-only chemicals. Because the published record is preclinical, regulatory discussion of lugdunin appears in the context of antibiotic discovery pipelines rather than prescribing.

Related glossary terms

• Fibupeptide — the structural class to which lugdunin was assigned, defined by its thiazolidine ring closure as described in the 2020 secretion and self-resistance study.
• lug operon — the gene cluster encoding biosynthesis, surveyed in the 2025 genomic study.
• Non-ribosomal peptide — the broader biosynthetic category, distinct from ribosomally translated peptides.

References

• The antimicrobial fibupeptide lugdunin forms water-filled channel structures in lipid membranes (Nature Communications, 2024)
• Secretion of and Self-Resistance to the Novel Fibupeptide Antimicrobial Lugdunin by Distinct ABC Transporters in Staphylococcus lugdunensis (Antimicrobial Agents and Chemotherapy, 2020)
• Synthetic Lugdunin Analogues Reveal Essential Structural Motifs for Antimicrobial Action and Proton Translocation Capability (Angewandte Chemie International Edition, 2019)
• Distinct Lugdunins from a New Efficient Synthesis and Broad Exploitation of Its MRSA-Antimicrobial Structure (Journal of Medicinal Chemistry, 2021)
• Lugdunin amplifies innate immune responses in the skin in synergy with host- and microbiota-derived factors (Nature Communications, 2019)
• The Staphylococcus aureus-antagonizing human nasal commensal Staphylococcus lugdunensis depends on siderophore piracy (Microbiome, 2024)
• Staphylococcus lugdunensis does not exert competitive exclusion on human corneocytes (Microbiology, 2025)
• Design, synthesis and Anti-Plasmodial activity of Mortiamide-Lugdunin conjugates (Bioorganic Chemistry, 2024)
• Study of lug Operon, SCCmec Elements, Antimicrobial Resistance, MGEs, and STs of Staphylococcus lugdunensis Clinical Isolates Through Whole-Genome Sequencing (International Journal of Molecular Sciences, 2025)
• Staphylococcus lugdunensis: a Skin Commensal with Invasive Pathogenic Potential (Clinical Microbiology Reviews, 2021)
• Antimicrobial Resistance and Antimicrobial Activity of Staphylococcus lugdunensis Obtained from Two Spanish Hospitals (Microorganisms, 2022)
• Phenotypic and genotypic characterization of clinical Staphylococcus lugdunensis isolates: a French retrospective cohort study (Microbiology Spectrum, 2026)